lamivudine HBV / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


1234567»
  • ||||||||||  Pricing, Journal:  A global comparison of hepatitis B & C drug pricing. (Pubmed Central) -  May 26, 2025   
    However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities.
  • ||||||||||  metformin / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Preclinical, Journal:  Impact of metformin on HBV replication: No evidence of suppression in vitro. (Pubmed Central) -  Apr 11, 2025   
    In HepAD38 cells, HBV replication is not impacted by metformin treatment. This contrasts with prior in vitro data but is in line with clinical evidence that suggests metformin acts through an influence on liver disease progression rather than a direct antiviral impact on HBV itself.
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Journal:  Design, Synthesis, and Bioevaluation of Matrine Derivatives as Potential Anti-Hepatitis B Virus Agents. (Pubmed Central) -  Mar 28, 2025   
    Of these, eleven compounds inhibited HBeAg secretion significantly more than the positive control, lamivudine (3TC)...These compounds inhibited viral gene expression and viral propagation in a cell culture model. Thus, we believe our compounds could serve as resource for antiviral drug development.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Diagnostic challenges due to hepatitis B virus surface antigen mutations outside the major hydrophilic region. (Pubmed Central) -  Mar 10, 2025   
    The OBI prevalence was higher in patients transplanted with HBsAg-negative liver grafts compared to blood donors, vaccinated young population, and community-based populations reported in literatures, possibly because of immune escape mutations or altered N-glycosylation patterns of surface proteins. Known OBI-associated mutations (S34L, P178R), a mutation resulting in a stop codon at position 196, associated with lamivudine-resistance, the substitution I81T,
  • ||||||||||  lamivudine HBV / Generic mfg.
    EVALUATING THE USE OF HEPATITIS B IMMUNOGLOBULIN POST LIVER TRANSPLANT (Halls C-E, Lower Level - SDCC) -  Mar 8, 2025 - Abstract #DDW2025DDW_4053;    
    These patients could be changed to tenofovir and have their HBIG ceased with monitoring as per protocol. This project demonstrates that patients receiving HBIG therapy should be more regularly reviewed for consideration of cessation in line with the guidelines.
  • ||||||||||  Preclinical, Journal:  Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. (Pubmed Central) -  Nov 13, 2024   
    This study evaluated the impact of lamivudine, dolutegravir (DTG), bictegravir (BIC), tenofovir disoproxil fumarate, and TAF on metabolic alterations, and explored glucose homeostasis and mitochondrial stress as potential mechanisms...BIC promoted mitochondrial dysfunction, modified carbohydrate metabolism and glucose consumption in hepatocytes, and altered glucose tolerance and gluconeogenesis regulation in mice. These findings suggest that BIC contributes to insulin resistance and diabetes in people living with HIV, warranting clinical studies to clarify its association with carbohydrate metabolism disorders.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Retrospective data, Journal:  Are nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B? (Pubmed Central) -  Oct 16, 2024   
    The aim of this study was to investigate the efficacy of tenofovir disoproxil fumarate (TDF) therapy and its effect on HBsAg seroconversion in patients with acute viral hepatitis B. The files of 126 patients who were under follow-up for acute HBV infection in the Department of Gastroenterology were analyzed retrospectively...It may reduce the development of natural immunity. Further studies are warranted.
  • ||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg.
    VIROLOGIC OUTCOME OF PEGINTERFERON FOR HBEAG-POSITIVE CHRONIC HEPATITIS B  () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1060;    
    Peginterferon treatment is associated with more HBeAg seroclearance but not HBsAg seroclearance over time compared with entecavir treatment in patients with positive HBeAg. Further analysis on virologic outcomes on the peginterferon group without censoring will reveal its role in achieving functional cure.
  • ||||||||||  Aptivus (tipranavir) / Boehringer Ingelheim, Edurant (rilpivirine) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
    Journal:  Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. (Pubmed Central) -  Sep 26, 2024   
    Among PI, resistance to tipranavir (0.8%), nelfinavir (0.6%), fosamprenavir (0.2%) and lopinavir (0.1%) was most frequent...The overall prevalence of PDR in Guangzhou was moderate, with relatively severe NNRTI resistance. Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV-infected individuals.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Complexities of Managing Chronic Hepatitis B in HIV: A Case of Acute Liver Injury Post-Medication Change (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3544;    
    On further history-taking, she reported a recent change in her HIV medication regimen from Efavirenz/Emtricitabine/Tenofovir to Dolutegravir/Rilpivirine in view of her worsening kidney function...Treatment with Entecavir and Lamivudine was initiated...As in our case, pegylated interferon or nucleos(t)ide analogues can be given to curb liver disease progression in affected individuals. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Transaminase Elevations Among Patients With Occult HBV Infection on 2-Drug Antiretroviral Regimens (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_876;    
    Whether OHBVI is associated with increased risk of transaminase elevation among those switching to two-drugs regimens (2DR), discontinuing lamivudine (3TC) and/or tenofovir (TFV), merits to be investigated.People living with HIV (PLWH) who had switched to a 2DR since 2018 were enrolled in this retrospective cohort, provided they had discontinued ?1 anti-HBV drug and that their anti-HBV core (HBc) status was known...Presence of OHBVI infection was not significantly associated with transaminase elevation among PLWH treated with 2DR lacking anti-HBV agents. This real-life observation provides reassurance regarding the safety of transitioning to dual therapy in patients with reactive anti-HBc.
  • ||||||||||  Rituxan (rituximab) / Roche
    REACTIVATION OF HEPATITIS B VIRUS ESCAPE MUTANTS IN A HBSAG NEGATIVE, ANTI-HBS POSITIVE PATIENT AFTER RITUXIMAB THERAPY (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_1898;    
    Transmission of the nucleoside induced mutants such as the lamivudine associated YMDD mutation could potentially result in the emergence of the G145A vaccine escape mutant...This structurally altered surface antigen cannot be detected by many commercially available EIA assays. For patients who need to receive B-cell depleting chemotherapy or other biologics that could potentially lead to severe HBVr, it is critical to check baseline HBV DNA level even if HBsAg was nonreactive so appropriate prophylaxis could be administered to prevent HBVr.
  • ||||||||||  lamivudine HBV / Generic mfg.
    HEPATITIS B VIRUS REACTIVATION IN CANCER PATIENTS RECEIVING CHEMOTHERAPY  (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_1859;    
    For patients who need to receive B-cell depleting chemotherapy or other biologics that could potentially lead to severe HBVr, it is critical to check baseline HBV DNA level even if HBsAg was nonreactive so appropriate prophylaxis could be administered to prevent HBVr. Among the 31 studies, the pooled HBV reactivation rates for patients who received prophylactic Tenofovir Disoproxil Fumarate (TDF) were 1% (95% CI: 0%
  • ||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Retrospective data, Review, Journal:  Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Nov 29, 2023   
    Lower baseline HBsAg levels, HBV genotype B, and elevated ALT levels during the first six months of ART are potential predictors of HBsAg seroclearance. There is insufficient evidence that NA obtain superior efficacy compared with placebo/standard-of-care in patients with acute viral hepatitis, based on low quality evidence.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Discovery of carboxyl-containing heteroaryldihydropyrimidine derivatives as novel HBV capsid assembly modulators with significantly improved metabolic stability. (Pubmed Central) -  Nov 17, 2023   
    The results from biological evaluation demonstrated that compound 6a-25 (EC = 0.020 ?M) exhibited greater potency than the positive drug lamivudine (EC = 0.09 ?M), and was comparable to the lead compound GLS4 (EC = 0.007 ?M)...Preliminary assessment of drug-likeness revealed that 6a-25 exhibited superior water solubility (pH 2.0: 374.81 ?g mL; pH 7.0: 6.85 ?g mL; pH 7.4: 25.48 ?g mL), liver microsomal metabolic stability (t = 108.2 min), and lower hERG toxicity (10 ?M inhibition rate was 72.66%) compared to the lead compound GLS4. Overall, compound 6a-25 holds promise for further investigation.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Bictegravir alters glucose tolerance and metabolism (MAZUREK) -  Sep 10, 2023 - Abstract #EACS2023EACS_304;    
    Lamivudine combined with methylprednisolone and leflunomide treatment is conducive to clearing Hepatitis B virus (HBV) and improving renal function. Purpose :
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Inhibition of Hepatitis B Virus (HBV) replication and antigen expression by Brucea javanica (L.) Merr. oil emulsion. (Pubmed Central) -  Aug 14, 2023   
    HepG2.215 (a wild-type HBV cell line), HepG2, and Huh7, transfected with wildtype (WT) or lamivudine-resistance mutant (LMV-MT) HBV replicon plasmids, were treated with different doses of BJOE and then used for pharmacodynamic evaluation...As one of the major components of BJOE, bruceine B was found to play a dominant role in IL-6 induction and HBV inhibition. Our results demonstrated that BJOE suppressed HBV replication by stimulating IL-6, indicating that it has promising clinical therapeutic potential for both WT and LMV-MT HBV.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico. (Pubmed Central) -  Aug 14, 2023   
    Lamivudine (3TC), telbivudine (LdT), entecavir (ETV), adefovir (ADF), and tenofovir (TFV) are drugs used to treat hepatitis B virus (HBV) infection, but specific mutations allow some viruses to become resistant to antiviral drugs or to acquire immune escape capacities...Resistance mutations were found in genotypes A2 (11.8%, 2/17), and H (10.2%, 11/108), and escape mutations were detected in HBV genotypes A2 (11.8%, 2/17), H (10.2%, 11/108), F1b (9.1%, 1/11) and G (5.6%, 1/18). The highest prevalence of antiviral resistance mutations or escape mutations was detected in HBV genotypes A2 and H. The earliest cases of HBV multidrug resistance were detected in Mexico.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Novel anti?hepatitis B virus flavonoids sakuranetin and velutin from Rhus (Pubmed Central) -  Aug 8, 2023   
    Drug?resistance in hepatitis B virus (HBV), especially due to prolonged treatment with nucleoside analogs, such as lamivudine (LAM), remains a clinical challenge...Furthermore, molecular docking of the flavonoids with HBV polymerase and capsid proteins revealed the formation of stable complexes with good docking energies, thus supporting their structure?based antiviral mechanism. In conclusion, the present study was the first to demonstrate the anti?HBV therapeutic activities of SEK and VEL isolated from R.